Method for the treatment of neurological or neuropsychiatric disorders

• US 6,310,085 B1
• Filed: 04/02/1999
• Issued: 10/30/2001
• Est. Priority Date: 10/03/1997
• Status: Expired due to Fees

• Current Assignee: Clarencew Pty Ltd.
• Original Assignee: Clarencew Pty Ltd.
• Inventors: Willis, Gregory Lynn
• Primary Examiner(s): Jarvis, William R. A.
• Application Number:
  US09/285,859
• Time in Patent Office: 942 Days
• Field of Search: 514/415
• US Class Current: 514/415
• CPC Class Codes: A61K 31/165 having aromatic rings, e.g. colchicine, atenolol, progabide
• CPC Class Codes: A61K 31/17 having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine isoureas, isothioureas A61K31/155; sulfonylureas A61K31/64
• CPC Class Codes: A61K 31/40 having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
• CPC Class Codes: A61K 31/4045 Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/495 having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazinesA61K31/48 takes precedence ; with three nitrogen atoms A61K31/53
• CPC Class Codes: A61K 31/4965 Non-condensed pyrazines
• CPC Class Codes: A61K 31/5375 1,4-Oxazines, e.g. morpholine
• CPC Class Codes: A61K 31/54 having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame

Abstract

This invention relates to a method for the treatment and/or prophylaxis of a neurological or neuropsychiatric disorder associated with altered dopamine function which comprises subjecting a patient in need thereof to therapy which blocks and/or inhibits melatonin, precursors thereof and/or metabolic products thereof.

Claims

1. A method for the treatment and/or prophylaxis of a neurological or neuropsychiatric disorder associated with altered dopamine function which comprises administering to a patient in need of such treatment or prophylaxis an effective amount of a compound of formula (1)

where X is —

NO₂ or —

N₃ and Y is H or I.

2. A method according to claim 1, wherein X is —

NO₂ and Y is H.

3. A method according to claim 1, wherein said neurological or neuropsychiatric disorder is selected from the group consisting of movement disorders and psychiatric disorders characterized by anxiety.

4. A method according to claim 3, wherein said neurological or neuropsychiatric disorder is selected from the group consisting of Huntingdon'"'"'s chorea, periodic limb movement syndrome, restless leg syndrome (akathesia), Tourrette'"'"'s syndrome, Sundowner'"'"'s syndrome, schizophrenia, Pick'"'"'s disease, Punch drunk syndrome, progressive subnuclear palsy, Korsakow'"'"'s (Korsakoff'"'"'s) syndrome, multiple sclerosis, Parkinson'"'"'s disease, malignant syndrome, acute dystonia, stroke, trans-ischemic attack, tardive dyskinesia and multiple systems atrophy (Parkinson'"'"'s plus).

5. A method according to claim 3, wherein the movement disorder is selected from Parkinson'"'"'s disease, schizophrenia, restless leg syndrome and tardive diskinesia.

6. A method according to claim 5, wherein the movement disorder is Parkinson'"'"'s disease.

7. A method according to claim 3, wherein said neurological or neuropsychiatric disorder is selected from the group consisting of panic disorder, agoraphobia, obsessive-compulsive disorder, post traumatic stress disorder, acute stress disorder, generalized anxiety disorder, and anxiety disorders due to depression.

8. A method according to claim 7, wherein said neurological or neuropsychiatric disorder is generalized anxiety disorder.

9. A method according to claim 1, wherein said neurological or neuropsychiatric disorder is anorexia cachexia or anorexia nervosa.

10. A method according to claim 1, wherein said neurological or neuropsychiatric disorder is Alzheimer'"'"'s disease or dementia.

11. A method according to claim 1 or 2, wherein said compound is administered in combination with light therapy.

12. A method according to claim 1 or 2, wherein said compound is administered in combination with surgical ablation or destruction of the pineal gland.

13. A method according to claim 1 or 2, wherein said compound is administered in combination with a drug which alters dopamine function.

14. A method according to claim 1 or 2, wherein said compound is administered in combination with a β

-adrenergic antagonist, a calcium channel blocker or a melanocyte stimulating hormone.

15. A method according to claim 13, wherein said drug therapy which alters dopamine function comprises the administration of a dopamine receptor blocker or a β

-adrenergic receptor antagonist.

16. A method according to claim 1 or 2, wherein said compound is administered within the range of 0.01 to 50 mg per kg body weight per day.

17. A method according to claim 16, wherein said compound is administered within the range of 0.5 to 10 mg per kg body weight per day.

18. A method according to claim 16, wherein said compound is administered as 2 to 6 sub-dose administrations throughout the day or in the form of a controlled release of the compound.

19. A method according to claim 1 or 2, wherein said compound is administered orally, by implant, rectally, by inhalation, by insufflation, topically, vaginally or parenterally.

20. A method according to claim 1 or 2, wherein said compound is administered in a composition further comprising one or more pharmaceutically acceptable carriers, diluents, adjuvants or excipients.